Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in Peripheral Arterial Disease
NCT01041417Phase 2Completed
- Sponsor
- Emory University
- Start
- Sep 2009
- Primary completion
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing GM-CSF with Placebo (2 arms). Primary endpoint: Change in Peak Walking Time During Treadmill Exercise Tolerance Test at 3 months. Started Sep 2009; status: completed.
02
Drugs
sargramostim
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT01041417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01041417.